The cardioprotective effects operate through the CD36 receptor, which is broadly expressed throughout the cardiovascular system
GLP-1 receptor agonists such as semaglutide and liraglutide are licensed in the UK for obesity management and work by mimicking gut hormones that regulate appetite and blood glucose
In the following part some of the postulated pathways that might contribute to the impaired glucose homeostasis will be briefly discussed
Introduction The global prevalence of obesity has surged dramatically over the past three decades, transforming into a pervasive health crisis with far-reaching societal and economic consequences (1)
Similarly, when increasing the minimum thresholds for average daily dose received in the analysis of MOF, differences between the two groups became larger and increasingly significant
Finally, disproportionality analysis based on FAERS showed neither causality nor quantified risk due to the lack of pharmacological mechanism study but only showed an evaluation of the signal strength, which was just a statistical association ( Conclusion We explored the relationship between GLP-1 RAs and gastrointestinal AEs from various perspectives and quantified the potential risks based on a comprehensive and systematic retrospective analysis of the FAERS database
